# Vertex to Acquire Crinetics Pharmaceuticals for ~$10 Billion

> ma · REPORTED · 2026-07-06

Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, representing a total equity value of approximately $10 billion. The deal adds PALSONIFY (paltusotine), an FDA-approved oral therapy for acromegaly, to Vertex's portfolio, with closing expected in Q3 2026.

About Vertex Pharmaceuticals / Crinetics Pharmaceuticals: Crinetics Pharmaceuticals is a San Diego-based biopharmaceutical company focused on discovering and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors, including its FDA-approved medicine PALSONIFY for acromegaly.

- Company: Vertex Pharmaceuticals / Crinetics Pharmaceuticals
- Sector: therapeutics
- Primary source: https://crinetics.com/press-releases/vertex-to-acquire-crinetics-pharmaceuticals/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.